within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AB05_Propantheline;

model Propantheline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.05,
    Cl = 1.1083333333333331e-05,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.0016699999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013833333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Propantheline</td></tr><tr><td>ATC code:</td><td>A03AB05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.67</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Propantheline is an antimuscarinic/anticholinergic agent used to treat peptic ulcers and various gastrointestinal disorders, as well as to reduce salivation and excessive sweating. It is not widely used today due to the availability of safer alternatives and its adverse side-effect profile.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Forrest, JA, et al., &amp; Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. <i>Clinical pharmacokinetics</i> 7(2) 93–107. DOI:<a href=\"https://doi.org/10.2165/00003088-198207020-00001\">10.2165/00003088-198207020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7039926/\">https://pubmed.ncbi.nlm.nih.gov/7039926</a></p></li><li><p>Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. <i>Clinical pharmacokinetics</i> 42(14) 1243–1285. DOI:<a href=\"https://doi.org/10.2165/00003088-200342140-00004\">10.2165/00003088-200342140-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14606931/\">https://pubmed.ncbi.nlm.nih.gov/14606931</a></p></li><li><p>Yarker, YE, et al., &amp; Fitton, A (1995). Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. <i>Drugs &amp; aging</i> 6(3) 243–262. DOI:<a href=\"https://doi.org/10.2165/00002512-199506030-00007\">10.2165/00002512-199506030-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7620236/\">https://pubmed.ncbi.nlm.nih.gov/7620236</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03AB05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Propantheline;
